Report and Recommendations on the Usefulness and Limitations of the Murine Local Lymph Node Assay for Potency Categorization of Chemicals Causing Allergic Contact Dermatitis in Humans, 45254-45256 [2011-18639]

Download as PDF 45254 Federal Register / Vol. 76, No. 145 / Thursday, July 28, 2011 / Notices rmajette on DSK89S0YB1PROD with NOTICES limit existing rights of the State of Alaska. DATES: All interested parties may request a public hearing. A request for a public hearing must be submitted by August 29, 2011 to the Regional Administrator at the EPA address shown below. Frivolous or insubstantial requests for a hearing may be denied by the Regional Administrator. However, if a substantial request for a public hearing is made by August 29, 2011, a public hearing will be held. If no timely and appropriate request for a hearing is received and the Regional Administrator does not elect to hold a hearing on his own motion, this determination shall become final and effective on August 29, 2011. Any request for a public hearing shall include the following information: (1) The name, address, and telephone number of the individual, organization, or other entity requesting a hearing; (2) a brief statement of the requesting person’s interest in the Regional Administrator’s determination and a brief statement of the information that the requesting person intends to submit at such hearing; (3) the signature of the individual making the request, or, if the request is made on behalf of an organization or other entity, the signature of a responsible official of the organization or other entity. ADDRESSES: All documents relating to this determination are available for inspection between the hours of 9 a.m. and 4 p.m., Monday through Friday, at the following offices: Alaska Department of Environmental Conservation (ADEC), 410 Willoughby, Suite 303, Juneau, Alaska 99801; ADEC South Central Regional Office, 555 Cordova Street, Anchorage, Alaska 99501; ADEC Northern Regional Office, 610 University Avenue, Fairbanks, Alaska 99709–3643 and between the hours of 9 a.m.–12 p.m. and 1–4 p.m. at the EPA Region 10 Library, 1200 Sixth Avenue, Seattle, Washington 98101. FOR FURTHER INFORMATION CONTACT: Wendy Marshall, EPA Region 10, Drinking Water Unit, by mail at the Seattle address given above, by telephone at (206) 553–1890, or by email at marshall.wendy@epa.gov. Authority: Section 1420 of the Safe Drinking Water Act, as amended (1996), and 40 CFR Part 142 of the National Primary Drinking Water Regulations. Dated: July 20, 2011. Dennis J. McLerran, Regional Administrator, Region 10. [FR Doc. 2011–19123 Filed 7–27–11; 8:45 am] BILLING CODE 6560–50–P VerDate Mar<15>2010 15:51 Jul 27, 2011 Jkt 223001 FEDERAL ELECTION COMMISSION Sunshine Act Notice AGENCY: Federal Election Commission. DATE AND TIME: Tuesday, August 2, 2011, Board of Governors of the Federal Reserve System, July 25, 2011. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2011–19099 Filed 7–27–11; 8:45 am] BILLING CODE 6210–01–P at 10 a.m. PLACE: 999 E Street, NW., Washington, DC. This meeting will be closed to the public. STATUS: Compliance matters pursuant to 2 U.S.C. 437g. Audits conducted pursuant to 2 U.S.C. 437g, 438(b), and Title 26, U.S.C. Matters concerning participation in civil actions or proceedings or arbitration. Internal personnel rules and procedures or matters affecting a particular employee. * * * * * ITEMS TO BE DISCUSSED: PERSON TO CONTACT FOR INFORMATION: Judith Ingram, Press Officer, Telephone: (202) 694–1220. Shelley E. Garr, Deputy Secretary of the Commission. [FR Doc. 2011–19297 Filed 7–26–11; 4:15 pm] BILLING CODE 6715–01–P FEDERAL RESERVE SYSTEM Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction This notice corrects a notice (FR Doc. 2011–17878) published on pages 41794 and 41795 of the issue for Friday, July 15, 2011. Under the Federal Reserve Bank of Richmond heading, the entry for BCSB Bancorp, Inc., Baltimore, Maryland, is revised to read as follows: A. Federal Reserve Bank of Richmond (Adam M. Drimer, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23261–4528: 1. BCSB Bancorp, Inc., Baltimore, Maryland, to become a bank holding company by acquiring 100 percent of the voting shares of Baltimore County Savings Bank Federal Savings Bank, Baltimore, Maryland, upon its conversion to a state-chartered commercial bank. In connection with this application, applicant has also applied to engage in lending activities, pursuant to section 225.28(b)(1) of Regulation Y. Comments on this application must be received by August 11, 2011. PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Report and Recommendations on the Usefulness and Limitations of the Murine Local Lymph Node Assay for Potency Categorization of Chemicals Causing Allergic Contact Dermatitis in Humans Division of the National Toxicology Program (DNTP), National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), HHS. ACTION: Availability of Report and Recommendations; Notice of Transmittal. AGENCY: The NTP Interagency Center for the Evaluation of Alternative Test Methods (NICEATM) announces availability of an Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) test method evaluation report (TMER) that includes recommendations on the usefulness and limitations of the local lymph node assay (LLNA) for categorizing the potency of substances with the potential to cause allergic contact dermatitis (ACD) as strong skin sensitizers. Strong skin sensitizers are substances considered to have a significant potential for causing ACD. ICCVAM recommends that a specific potency criterion for positive results from ACD safety testing using the LLNA can be used to further categorize some chemicals and products as strong skin sensitizers. However, since this criterion only identified approximately half of strong human skin sensitizers, ICCVAM concluded that failure to meet this criterion cannot be used as the basis for determining that a substance is not a strong skin sensitizer. Therefore, the potency criterion should only be used in a screening approach where chemicals that meet the criterion could be categorized as strong skin sensitizers, but chemicals that do not meet the criterion would require additional testing or information to determine that they are not strong skin sensitizers. The report and recommendations have been transmitted to Federal agencies for their review and response to ICCVAM in accordance with the provisions of the ICCVAM SUMMARY: E:\FR\FM\28JYN1.SGM 28JYN1 Federal Register / Vol. 76, No. 145 / Thursday, July 28, 2011 / Notices Authorization Act of 2000 (42 U.S.C. 285l-2). FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, Director, NICEATM, NIEHS, P.O. Box 12233, Mail Stop: K2– 16, Research Triangle Park, NC 27709, (telephone) 919–541–2384, (fax) 919– 541–0947, (e-mail) niceatm@niehs.nih.gov. Courier address: NICEATM, NIEHS, Room 2034, 530 Davis Drive, Morrisville, NC 27560. SUPPLEMENTARY INFORMATION: rmajette on DSK89S0YB1PROD with NOTICES Background In 1999, ICCVAM evaluated the validation status of the LLNA as a standalone alternative test method to the guinea pig maximization test (GPMT) and the Buehler test (BT) for assessing the ACD hazard potential of products and chemicals (NIH Publication No. 99– 4494; https://iccvam.niehs.nih.gov/ methods/immunotox/llna_ PeerPanel98.htm). Based on this evaluation, ICCVAM recommended the LLNA as a valid substitute for traditional guinea pig test methods for most testing situations. The U.S. Environmental Protection Agency, the U.S. Food and Drug Administration, and the U.S. Consumer Product Safety Commission (CPSC) subsequently accepted the method as a valid substitute for the GPMT and BT. The Organisation for Economic Co-operation and Development (OECD) also adopted the LLNA as OECD Test Guideline 429 in 2002. Using the LLNA instead of guinea pig tests reduces and refines (decreases or eliminates pain and distress) animal use for ACD safety testing. In 2007, the CPSC nominated several new versions and applications of the LLNA to ICCVAM for evaluation of their scientific validity for regulatory testing purposes (https://iccvam.niehs.nih.gov/ methods/immunotox/llnadocs/CPSC_ LLNA_nom.pdf). The nomination requested that ICCVAM assess (1) the validation status of the LLNA limit dose procedure (i.e., the reduced LLNA); (2) the modified LLNA test method protocols that do not require the use of radioactive materials; (3) the use of the LLNA to test mixtures, aqueous solutions, and metals; and (4) the use of the LLNA as a stand-alone assay to determine ACD potency categories for hazard classification and labeling. NICEATM published a Federal Register notice (72 FR 27815) requesting public comments on (1) The appropriateness and relative priority of the CPSCnominated LLNA activities, (2) the nomination of scientists to serve on an international independent scientific peer review panel, and (3) the VerDate Mar<15>2010 15:51 Jul 27, 2011 Jkt 223001 submission of data from LLNA testing that related to the CPSC-nominated LLNA activities as well as corresponding data from human and other animal studies. ICCVAM assigned these activities a high priority after considering comments from the public and endorsement from the Scientific Advisory Committee on Alternative Toxicological Methods (SACATM). NICEATM and ICCVAM compiled comprehensive draft background review documents (BRDs), released them for public comment in January 2008 (73 FR 1360), and convened a public meeting of the panel on March 4–6, 2008, to peer review the draft documents. The panel evaluated the information in the draft BRDs as to whether it supported draft ICCVAM recommendations for (1) Test method usefulness and limitations, (2) updated standardized test method protocols, and (3) proposed future studies. The panel considered public comments made at the meeting, as well as public comments submitted in advance of the meeting, before concluding their deliberations. The panel’s report was made available in May 2008 (73 FR 29136) for public comment. The draft ICCVAM BRDs, draft ICCVAM test method recommendations, the panel’s report, and all public comments were made available to SACATM for comment at its meeting on June 18–19, 2008 (73 FR 25754). After considering the conclusions and recommendations of the panel, comments from SACATM, and public comments, ICCVAM forwarded final recommendations for the reduced LLNA (NIH Publication No. 09–6439; https:// iccvam.niehs.nih.gov/methods/ immunotox/LLNA-LD/TMER.htm), LLNA performance standards, and the updated LLNA test method protocol (NIH Publication No. 09–7357; https:// iccvam.niehs.nih.gov/methods/ immunotox/llna_PerfStds.htm) to Federal agencies in September 2009 (74 FR 50212). Agency responses are available on the NICEATM–ICCVAM Web site. NICEATM subsequently obtained additional data and/or information and revised the draft BRDs for both the traditional and nonradioactive LLNA methods. ICCVAM released the revised draft BRDs and the revised draft ICCVAM test method recommendations to the public for comment and announced a second meeting of the panel (74 FR 8974). The panel reconvened in public session on April 28–29, 2009, to review the ICCVAMrevised draft documents and to finalize its conclusions and recommendations on the current validation status of the PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 45255 nonradioactive test methods and the expanded uses of the LLNA for pesticide formulations and other products. The panel’s report was made available for public comment in June 2009 (74 FR 26242). The revised draft ICCVAM BRDs, revised draft ICCVAM test method recommendations, the panel’s report, and all public comments were made available to SACATM for comment on June 25–26, 2009 (74 FR 19562). After considering the conclusions and recommendations of the panel, comments from SACATM, and public comments, along with the recommendations of an OECD Expert Consultation on the LLNA convened in October and December 2009, ICCVAM finalized and forwarded test method recommendations on two nonradioactive versions of the LLNA, LLNA: 5-Bromo-2′-deoxyuridineEnzyme-Linked Immunosorbent Assay (BrdU–ELISA) (NIH Publication No. 10– 7552; https://iccvam.niehs.nih.gov/ methods/immunotox/llna-ELISA/ TMER.htm) and LLNA: Daicel Adenosine Triphosphate (DA) (NIH Publication No. 10–7551; https:// iccvam.niehs.nih.gov/methods/ immunotox/llna-DA/TMER.htm), and expanded uses of the LLNA for pesticide formulations and other products (NIH Publication No. 10–7512; https://iccvam.niehs.nih.gov/methods/ immunotox/llna-app.htm) to Federal agencies in June 2010 (75 FR 37443). Agency responses to these ICCVAM test method recommendations are available on the NICEATM–ICCVAM Web site. The ICCVAM TMER, Usefulness and Limitations of the Murine Local Lymph Node Assay for Potency Categorization of Chemicals Causing Allergic Contact Dermatitis in Humans (NIH Publication No. 11–7709), describes ICCVAM’s recommendations for using LLNA test results to categorize the potency of some substances identified as having the potential to cause ACD in humans as strong skin sensitizers. Strong sensitizers are those substances considered to have a significant potential for causing hypersensitivity. ICCVAM recommends that a specific potency criterion for positive results from ACD safety testing using the LLNA can be used to further categorize some chemicals and products as strong skin sensitizers. However, since this criterion only identified approximately half of the strong human skin sensitizers tested, failure to meet this criterion cannot be used as the basis for determining that a substance is not a strong skin sensitizer. Therefore, the potency criterion should only be used in a screening approach where chemicals that meet the criterion E:\FR\FM\28JYN1.SGM 28JYN1 45256 Federal Register / Vol. 76, No. 145 / Thursday, July 28, 2011 / Notices rmajette on DSK89S0YB1PROD with NOTICES could be categorized as strong skin sensitizers, but chemicals that do not meet the criterion would require additional testing or information to determine that they are not strong skin sensitizers. The ICCVAM evaluation found that only 52% of the strong human skin sensitizers in the validation database would be identified as strong skin sensitizers using the LLNA potency criterion in the 2009 United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS). Accordingly, chemicals that do not meet the criterion would require additional testing or information to determine that a substance is not a strong human skin sensitizer. Background Information on ICCVAM, NICEATM, and SACATM ICCVAM is an interagency committee composed of representatives from 15 Federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. ICCVAM conducts technical evaluations of new, revised, and alternative safety testing methods with regulatory applicability and promotes the scientific validation and regulatory acceptance of toxicological and safety testing methods that more accurately assess the safety and hazards of chemicals and products and that reduce, refine (decrease or eliminate pain and distress), or replace animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l–3) established ICCVAM as a permanent interagency committee of the NIEHS under NICEATM. NICEATM administers ICCVAM, provides scientific and operational support for ICCVAM-related activities, and conducts independent validation studies to assess the usefulness and limitations of new, revised, and alternative test methods and strategies. NICEATM and ICCVAM welcome the public nomination of new, revised, and alternative test methods and strategies applicable to the needs of U.S. Federal agencies. Additional information about NICEATM and ICCVAM can be found on the NICEATM–ICCVAM Web site (https:// iccvam.niehs.nih.gov). SACATM was established in response to the ICCVAM Authorization Act [Section 285l–3(d)] and is composed of scientists from the public and private sectors (67 FR 11358). SACATM advises ICCVAM, NICEATM, and the Director of the NIEHS and NTP regarding statutorily mandated duties of ICCVAM and activities of NICEATM. SACATM provides advice on priorities and VerDate Mar<15>2010 15:51 Jul 27, 2011 Jkt 223001 activities related to the development, validation, scientific review, regulatory acceptance, implementation, and national and international harmonization of new, revised, and alternative toxicological test methods. Additional information about SACATM, including the charter, roster, and records of past meetings, can be found at https://ntp.niehs.nih.gov/go/167. References ICCVAM. 2011. ICCVAM Test Method Evaluation Report: Usefulness and Limitations of the Murine Local Lymph Node Assay for Potency Categorization of Chemicals Causing Allergic Contact Dermatitis in Humans. NIH Publication No. 11–7709. Research Triangle Park, NC: National Institute of Environmental Health Sciences. Available at: https:// iccvam.niehs.nih.gov/methods/ immunotox/llna-ELISA/LLNA-pot/ TMER.htm. ICCVAM. 2010. ICCVAM Test Method Evaluation Report on the Murine Local Lymph Node Assay: BrdU–ELISA, a Nonradioactive Alternative Test Method to Assess the Allergic Contact Dermatitis Potential of Chemicals and Products. NIH Publication No. 10–7552. Research Triangle Park, NC: National Institute of Environmental Health Sciences. Available at: https:// iccvam.niehs.nih.gov/methods/ immunotox/llna-ELISA/TMER.htm. ICCVAM. 2010. ICCVAM Test Method Evaluation Report on the Murine Local Lymph Node Assay: DA, a Nonradioactive Alternative Test Method to Assess the Allergic Contact Dermatitis Potential of Chemicals and Products. NIH Publication No. 10–7551. Research Triangle Park, NC: National Institute of Environmental Health Sciences. Available at: https:// iccvam.niehs.nih.gov/methods/ immunotox/llna-DA/TMER.htm. ICCVAM. 2010. ICCVAM Test Method Evaluation Report on Using the Murine Local Lymph Node Assay for Testing Pesticide Formulations, Metals, Substances in Aqueous Solutions, and Other Products. NIH Publication No. 10–7512. Research Triangle Park, NC: National Institute of Environmental Health Sciences. Available at: https:// iccvam.niehs.nih.gov/methods/ immunotox/LLNA-app/TMER.htm. ICCVAM. 2009. Recommended Performance Standards: Murine Local Lymph Node Assay. NIH Publication No. 09–7357. Research Triangle Park, NC: National Institute of Environmental Health Sciences. Available at: https:// iccvam.niehs.nih.gov/methods/ immunotox/llna_PerfStds.htm. ICCVAM. 2009. ICCVAM Test Method Evaluation Report. The Reduced Murine PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 Local Lymph Node Assay: An Alternative Test Method Using Fewer Animals to Assess the Allergic Contact Dermatitis Potential of Chemicals and Products. NIH Publication No. 09–6439. Research Triangle Park, NC: National Institute of Environmental Health Sciences. Available at: https:// iccvam.niehs.nih.gov/methods/ immunotox/LLNA–LD/TMER.htm. ICCVAM. 1999. The Murine Local Lymph Node Assay: A Test Method for Assessing the Allergic Contact Dermatitis Potential of Chemicals/ Compounds. The Results of an Independent Peer Review Evaluation Coordinated by ICCVAM and NICEATM. NIH Publication No. 99– 4494. Research Triangle Park, NC: National Institute of Environmental Health Sciences. Available at: https:// iccvam.niehs.nih.gov/methods/ immunotox/llna_PeerPanel98.htm. Dated: July 14, 2011. John R. Bucher, Associate Director, National Toxicology Program. [FR Doc. 2011–18639 Filed 7–27–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–11–11EM] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC, or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice. Proposed Project National Survey of Primary Care Policies for Managing Patients with High Blood Pressure, High Cholesterol, or Diabetes—New—Division of Heart Disease and Stroke Prevention (DHDSP), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC). E:\FR\FM\28JYN1.SGM 28JYN1

Agencies

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 76, Number 145 (Thursday, July 28, 2011)]
[Notices]
[Pages 45254-45256]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-18639]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Report and Recommendations on the Usefulness and Limitations of 
the Murine Local Lymph Node Assay for Potency Categorization of 
Chemicals Causing Allergic Contact Dermatitis in Humans

AGENCY: Division of the National Toxicology Program (DNTP), National 
Institute of Environmental Health Sciences (NIEHS), National Institutes 
of Health (NIH), HHS.

ACTION: Availability of Report and Recommendations; Notice of 
Transmittal.

-----------------------------------------------------------------------

SUMMARY: The NTP Interagency Center for the Evaluation of Alternative 
Test Methods (NICEATM) announces availability of an Interagency 
Coordinating Committee on the Validation of Alternative Methods 
(ICCVAM) test method evaluation report (TMER) that includes 
recommendations on the usefulness and limitations of the local lymph 
node assay (LLNA) for categorizing the potency of substances with the 
potential to cause allergic contact dermatitis (ACD) as strong skin 
sensitizers. Strong skin sensitizers are substances considered to have 
a significant potential for causing ACD.
    ICCVAM recommends that a specific potency criterion for positive 
results from ACD safety testing using the LLNA can be used to further 
categorize some chemicals and products as strong skin sensitizers. 
However, since this criterion only identified approximately half of 
strong human skin sensitizers, ICCVAM concluded that failure to meet 
this criterion cannot be used as the basis for determining that a 
substance is not a strong skin sensitizer. Therefore, the potency 
criterion should only be used in a screening approach where chemicals 
that meet the criterion could be categorized as strong skin 
sensitizers, but chemicals that do not meet the criterion would require 
additional testing or information to determine that they are not strong 
skin sensitizers.
    The report and recommendations have been transmitted to Federal 
agencies for their review and response to ICCVAM in accordance with the 
provisions of the ICCVAM

[[Page 45255]]

Authorization Act of 2000 (42 U.S.C. 285l-2).

FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, Director, 
NICEATM, NIEHS, P.O. Box 12233, Mail Stop: K2-16, Research Triangle 
Park, NC 27709, (telephone) 919-541-2384, (fax) 919-541-0947, (e-mail) 
niceatm@niehs.nih.gov. Courier address: NICEATM, NIEHS, Room 2034, 530 
Davis Drive, Morrisville, NC 27560.

SUPPLEMENTARY INFORMATION: 

Background

    In 1999, ICCVAM evaluated the validation status of the LLNA as a 
stand-alone alternative test method to the guinea pig maximization test 
(GPMT) and the Buehler test (BT) for assessing the ACD hazard potential 
of products and chemicals (NIH Publication No. 99-4494; https://iccvam.niehs.nih.gov/methods/immunotox/llna_PeerPanel98.htm). Based on 
this evaluation, ICCVAM recommended the LLNA as a valid substitute for 
traditional guinea pig test methods for most testing situations. The 
U.S. Environmental Protection Agency, the U.S. Food and Drug 
Administration, and the U.S. Consumer Product Safety Commission (CPSC) 
subsequently accepted the method as a valid substitute for the GPMT and 
BT. The Organisation for Economic Co-operation and Development (OECD) 
also adopted the LLNA as OECD Test Guideline 429 in 2002. Using the 
LLNA instead of guinea pig tests reduces and refines (decreases or 
eliminates pain and distress) animal use for ACD safety testing.
    In 2007, the CPSC nominated several new versions and applications 
of the LLNA to ICCVAM for evaluation of their scientific validity for 
regulatory testing purposes (https://iccvam.niehs.nih.gov/methods/immunotox/llnadocs/CPSC_LLNA_nom.pdf). The nomination requested that 
ICCVAM assess (1) the validation status of the LLNA limit dose 
procedure (i.e., the reduced LLNA); (2) the modified LLNA test method 
protocols that do not require the use of radioactive materials; (3) the 
use of the LLNA to test mixtures, aqueous solutions, and metals; and 
(4) the use of the LLNA as a stand-alone assay to determine ACD potency 
categories for hazard classification and labeling. NICEATM published a 
Federal Register notice (72 FR 27815) requesting public comments on (1) 
The appropriateness and relative priority of the CPSC-nominated LLNA 
activities, (2) the nomination of scientists to serve on an 
international independent scientific peer review panel, and (3) the 
submission of data from LLNA testing that related to the CPSC-nominated 
LLNA activities as well as corresponding data from human and other 
animal studies. ICCVAM assigned these activities a high priority after 
considering comments from the public and endorsement from the 
Scientific Advisory Committee on Alternative Toxicological Methods 
(SACATM). NICEATM and ICCVAM compiled comprehensive draft background 
review documents (BRDs), released them for public comment in January 
2008 (73 FR 1360), and convened a public meeting of the panel on March 
4-6, 2008, to peer review the draft documents. The panel evaluated the 
information in the draft BRDs as to whether it supported draft ICCVAM 
recommendations for (1) Test method usefulness and limitations, (2) 
updated standardized test method protocols, and (3) proposed future 
studies. The panel considered public comments made at the meeting, as 
well as public comments submitted in advance of the meeting, before 
concluding their deliberations. The panel's report was made available 
in May 2008 (73 FR 29136) for public comment. The draft ICCVAM BRDs, 
draft ICCVAM test method recommendations, the panel's report, and all 
public comments were made available to SACATM for comment at its 
meeting on June 18-19, 2008 (73 FR 25754).
    After considering the conclusions and recommendations of the panel, 
comments from SACATM, and public comments, ICCVAM forwarded final 
recommendations for the reduced LLNA (NIH Publication No. 09-6439; 
https://iccvam.niehs.nih.gov/methods/immunotox/LLNA-LD/TMER.htm), LLNA 
performance standards, and the updated LLNA test method protocol (NIH 
Publication No. 09-7357; https://iccvam.niehs.nih.gov/methods/immunotox/llna_PerfStds.htm) to Federal agencies in September 2009 (74 FR 
50212). Agency responses are available on the NICEATM-ICCVAM Web site.
    NICEATM subsequently obtained additional data and/or information 
and revised the draft BRDs for both the traditional and nonradioactive 
LLNA methods. ICCVAM released the revised draft BRDs and the revised 
draft ICCVAM test method recommendations to the public for comment and 
announced a second meeting of the panel (74 FR 8974). The panel 
reconvened in public session on April 28-29, 2009, to review the 
ICCVAM-revised draft documents and to finalize its conclusions and 
recommendations on the current validation status of the nonradioactive 
test methods and the expanded uses of the LLNA for pesticide 
formulations and other products. The panel's report was made available 
for public comment in June 2009 (74 FR 26242). The revised draft ICCVAM 
BRDs, revised draft ICCVAM test method recommendations, the panel's 
report, and all public comments were made available to SACATM for 
comment on June 25-26, 2009 (74 FR 19562).
    After considering the conclusions and recommendations of the panel, 
comments from SACATM, and public comments, along with the 
recommendations of an OECD Expert Consultation on the LLNA convened in 
October and December 2009, ICCVAM finalized and forwarded test method 
recommendations on two nonradioactive versions of the LLNA, LLNA: 5-
Bromo-2'-deoxyuridine-Enzyme-Linked Immunosorbent Assay (BrdU-ELISA) 
(NIH Publication No. 10-7552; https://iccvam.niehs.nih.gov/methods/immunotox/llna-ELISA/TMER.htm) and LLNA: Daicel Adenosine Triphosphate 
(DA) (NIH Publication No. 10-7551; https://iccvam.niehs.nih.gov/methods/immunotox/llna-DA/TMER.htm), and expanded uses of the LLNA for 
pesticide formulations and other products (NIH Publication No. 10-7512; 
https://iccvam.niehs.nih.gov/methods/immunotox/llna-app.htm) to Federal 
agencies in June 2010 (75 FR 37443). Agency responses to these ICCVAM 
test method recommendations are available on the NICEATM-ICCVAM Web 
site.
    The ICCVAM TMER, Usefulness and Limitations of the Murine Local 
Lymph Node Assay for Potency Categorization of Chemicals Causing 
Allergic Contact Dermatitis in Humans (NIH Publication No. 11-7709), 
describes ICCVAM's recommendations for using LLNA test results to 
categorize the potency of some substances identified as having the 
potential to cause ACD in humans as strong skin sensitizers. Strong 
sensitizers are those substances considered to have a significant 
potential for causing hypersensitivity. ICCVAM recommends that a 
specific potency criterion for positive results from ACD safety testing 
using the LLNA can be used to further categorize some chemicals and 
products as strong skin sensitizers. However, since this criterion only 
identified approximately half of the strong human skin sensitizers 
tested, failure to meet this criterion cannot be used as the basis for 
determining that a substance is not a strong skin sensitizer. 
Therefore, the potency criterion should only be used in a screening 
approach where chemicals that meet the criterion

[[Page 45256]]

could be categorized as strong skin sensitizers, but chemicals that do 
not meet the criterion would require additional testing or information 
to determine that they are not strong skin sensitizers.
    The ICCVAM evaluation found that only 52% of the strong human skin 
sensitizers in the validation database would be identified as strong 
skin sensitizers using the LLNA potency criterion in the 2009 United 
Nations Globally Harmonized System of Classification and Labelling of 
Chemicals (GHS). Accordingly, chemicals that do not meet the criterion 
would require additional testing or information to determine that a 
substance is not a strong human skin sensitizer.

Background Information on ICCVAM, NICEATM, and SACATM

    ICCVAM is an interagency committee composed of representatives from 
15 Federal regulatory and research agencies that require, use, 
generate, or disseminate toxicological and safety testing information. 
ICCVAM conducts technical evaluations of new, revised, and alternative 
safety testing methods with regulatory applicability and promotes the 
scientific validation and regulatory acceptance of toxicological and 
safety testing methods that more accurately assess the safety and 
hazards of chemicals and products and that reduce, refine (decrease or 
eliminate pain and distress), or replace animal use. The ICCVAM 
Authorization Act of 2000 (42 U.S.C. 285l-3) established ICCVAM as a 
permanent interagency committee of the NIEHS under NICEATM. NICEATM 
administers ICCVAM, provides scientific and operational support for 
ICCVAM-related activities, and conducts independent validation studies 
to assess the usefulness and limitations of new, revised, and 
alternative test methods and strategies. NICEATM and ICCVAM welcome the 
public nomination of new, revised, and alternative test methods and 
strategies applicable to the needs of U.S. Federal agencies. Additional 
information about NICEATM and ICCVAM can be found on the NICEATM-ICCVAM 
Web site (https://iccvam.niehs.nih.gov).
    SACATM was established in response to the ICCVAM Authorization Act 
[Section 285l-3(d)] and is composed of scientists from the public and 
private sectors (67 FR 11358). SACATM advises ICCVAM, NICEATM, and the 
Director of the NIEHS and NTP regarding statutorily mandated duties of 
ICCVAM and activities of NICEATM. SACATM provides advice on priorities 
and activities related to the development, validation, scientific 
review, regulatory acceptance, implementation, and national and 
international harmonization of new, revised, and alternative 
toxicological test methods. Additional information about SACATM, 
including the charter, roster, and records of past meetings, can be 
found at https://ntp.niehs.nih.gov/go/167.

References

    ICCVAM. 2011. ICCVAM Test Method Evaluation Report: Usefulness and 
Limitations of the Murine Local Lymph Node Assay for Potency 
Categorization of Chemicals Causing Allergic Contact Dermatitis in 
Humans. NIH Publication No. 11-7709. Research Triangle Park, NC: 
National Institute of Environmental Health Sciences. Available at: 
https://iccvam.niehs.nih.gov/methods/immunotox/llna-ELISA/LLNA-pot/TMER.htm.
    ICCVAM. 2010. ICCVAM Test Method Evaluation Report on the Murine 
Local Lymph Node Assay: BrdU-ELISA, a Nonradioactive Alternative Test 
Method to Assess the Allergic Contact Dermatitis Potential of Chemicals 
and Products. NIH Publication No. 10-7552. Research Triangle Park, NC: 
National Institute of Environmental Health Sciences. Available at: 
https://iccvam.niehs.nih.gov/methods/immunotox/llna-ELISA/TMER.htm.
    ICCVAM. 2010. ICCVAM Test Method Evaluation Report on the Murine 
Local Lymph Node Assay: DA, a Nonradioactive Alternative Test Method to 
Assess the Allergic Contact Dermatitis Potential of Chemicals and 
Products. NIH Publication No. 10-7551. Research Triangle Park, NC: 
National Institute of Environmental Health Sciences. Available at: 
https://iccvam.niehs.nih.gov/methods/immunotox/llna-DA/TMER.htm.
    ICCVAM. 2010. ICCVAM Test Method Evaluation Report on Using the 
Murine Local Lymph Node Assay for Testing Pesticide Formulations, 
Metals, Substances in Aqueous Solutions, and Other Products. NIH 
Publication No. 10-7512. Research Triangle Park, NC: National Institute 
of Environmental Health Sciences. Available at: https://iccvam.niehs.nih.gov/methods/immunotox/LLNA-app/TMER.htm.
    ICCVAM. 2009. Recommended Performance Standards: Murine Local Lymph 
Node Assay. NIH Publication No. 09-7357. Research Triangle Park, NC: 
National Institute of Environmental Health Sciences. Available at: 
https://iccvam.niehs.nih.gov/methods/immunotox/llna_PerfStds.htm.
    ICCVAM. 2009. ICCVAM Test Method Evaluation Report. The Reduced 
Murine Local Lymph Node Assay: An Alternative Test Method Using Fewer 
Animals to Assess the Allergic Contact Dermatitis Potential of 
Chemicals and Products. NIH Publication No. 09-6439. Research Triangle 
Park, NC: National Institute of Environmental Health Sciences. 
Available at: https://iccvam.niehs.nih.gov/methods/immunotox/LLNA-LD/TMER.htm.
    ICCVAM. 1999. The Murine Local Lymph Node Assay: A Test Method for 
Assessing the Allergic Contact Dermatitis Potential of Chemicals/
Compounds. The Results of an Independent Peer Review Evaluation 
Coordinated by ICCVAM and NICEATM. NIH Publication No. 99-4494. 
Research Triangle Park, NC: National Institute of Environmental Health 
Sciences. Available at: https://iccvam.niehs.nih.gov/methods/immunotox/llna_PeerPanel98.htm.

    Dated: July 14, 2011.
John R. Bucher,
Associate Director, National Toxicology Program.
[FR Doc. 2011-18639 Filed 7-27-11; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.